Blueprint Medicines Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Blueprint Medicines (BPMC) Misses Q3 EPS by 37c
October 28, 2021 7:06 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.00), $0.37 worse than the analyst estimate of ($1.63).
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More